MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

NCT05462236 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Tinodasertib
DRUG: Pembrolizumab
DRUG: Irinotecan

Sponsor

AUM Biosciences Pte Ltd

Collaborators

[object Object]